Clarivate Plc a leading global provider of transformative intelligence, announced the appointment of Michael Easton as Executive Vice President and Chief Financial Officer, effective August 8, 2026. He succeeds Jonathan Collins who is stepping down as CFO to pursue another opportunity.
Mr. Easton is a tenured finance executive of the Company and brings more than 25 years of experience in finance, accounting and operations to the role. He most recently served as Senior Vice President and Chief Accounting Officer, leading Clarivate’s core financial reporting and planning functions and playing a critical role in strengthening financial discipline, enhancing governance and controls and driving operational excellence across the Company. As EVP and CFO, Mr. Easton will focus on advancing Clarivate’s strategic priorities, including accelerating growth, improving profitability, strengthening free cash flow generation and maintaining disciplined capital allocation.
Also Read: Cognyte Appoints Adam Philpott as Chief Revenue Officer to Lead Global Market Expansion
“Michael is a highly respected leader whose financial expertise, strategic insight and institutional knowledge will be invaluable in sustaining our momentum and advancing our growth strategy,” said Matti Shem Tov, Chief Executive Officer of Clarivate. “His appointment underscores the strength of our leadership bench and our commitment to thoughtful succession planning, and I am confident he will help us deliver sustainable growth and long-term shareholder value.”
“I am honored to serve as EVP and CFO and appreciate the confidence Matti and our Board have placed in me,” said Mr. Easton. “Clarivate has a strong foundation, an exceptional team and significant opportunities ahead. My focus will be on disciplined execution – building on our momentum, working across the Company to accelerate growth and translating our strategic priorities into lasting value for our customers and shareholders.”
Mr. Shem Tov added, “We appreciate Jonathan’s many contributions to Clarivate during an important transformation period. He brought rigor to our financial management and execution and translated key strategic initiatives and priorities into action, including the planned divestiture of our Life Sciences & Healthcare segment. We wish him every success in the future.”
SOURCE: PRNewswire
